Informational Only · Not Veterinary Advice · Consult Your Vet · Editorial Policy

Portela: New VMD-Approved Pain Therapy for Arthritic Cats

Portela is a new VMD-approved therapy for pain linked to osteoarthritis in cats. Zoetis announced on July 30, 2026 that the UK Veterinary Medicines Directorate approved Portela (relfovetmab injection) for alleviation of that pain Zoetis approval announcement. Osteoarthritis is long-term joint breakdown that causes stiffness and pain. Portela offers up to three months of relief from one injection, which may suit cats that resist daily medicine.

Table of Contents

How does Portela relieve arthritis pain?

Portela contains relfovetmab, a laboratory-made antibody given by injection. It targets nerve growth factor, called NGF, a key driver of osteoarthritis pain and inflammation in cats. An anti-NGF monoclonal antibody binds NGF and blocks its pain signal.

That action is selective for the NGF pathway rather than broad sedation. The result is pain relief that lasts after a single dose. Zoetis describes Portela as the first long-acting feline anti-NGF antibody therapy. A single subcutaneous injection can relieve pain for up to three months.

How is the injection given?

Portela is given under the skin by a veterinary professional. The UK VMD product information sets the dose at 0.5–1.25 mg/kg once every three months VMD product summary. The product uses 2.5 mg and 6.4 mg single-use vials by weight band.

The clinic selects the vial and volume for the cat's weight. Owners do not dose at home. That schedule means one clinic visit every three months for treatment. It removes daily pilling, liquid dosing, and missed doses for eligible cats.

Which cats may need it?

Arthritis is common and often missed because cats hide discomfort. Reports cite up to 40% of cats with clinical signs, about 60% over age 6 with X-ray changes, and about 90% over age 12. Watch for slower jumping, stiff rising, shorter play, missed litter-box edges, and less grooming.

Older cats may sleep more or avoid stairs. These changes deserve a veterinary arthritis check. A nine-month European field trial found better owner-assessed outcomes and steady veterinarian-assessed pain reduction over 270 days, according to dvm360 reporting on Zoetis data trial report. The same report included tolerability data in cats with IRIS stage 1–3 kidney disease.

What are the limits and next steps?

Joint X-rays were taken only at screening in the product program. UK VMD product information states that possible effects on osteoarthritis progression were not investigated radiographically VMD product information. Portela is a veterinary prescription product.

It requires a diagnosis, weight-based dosing, and clinic follow-up. It does not replace weight control, joint-friendly home changes, or treatment for other illness. Ask the clinic at the visit:.

  • Is my cat's stiffness likely osteoarthritis pain?
  • What weight band and follow-up date apply?
  • What mobility changes should I track at home?
  • When should we return sooner than three months?

You Might Also Like

We use cookies to run this site, measure how it’s used, and show ads. Choose “Essentials only” to limit cookies to what the site needs to work.